- $4.37m
- $4.50m
- $6.59m
- 50
- 54
- 16
- 34
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 2.35 | ||
| Price to Tang. Book | 2.58 | ||
| Price to Free Cashflow | 17.3 | ||
| Price to Sales | 0.67 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -18.42% | ||
| Return on Equity | -25.04% | ||
| Operating Margin | -7.38% | ||
Financial Summary
| Year End 31st Mar | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 7.67 | 7.54 | 7.67 | 7.35 | 6.59 | n/a | n/a | -5.64% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Encision Inc. is a medical device company. It designs, develops, manufactures and markets patented surgical instruments that provide safety to patients undergoing minimally invasive surgery. Its segments include Product and Service. Product segment designs, develops, manufactures and markets patented surgical instruments. Service segment performs electrical engineering activities for external entities. Its Active Electrode Monitoring (AEM) technology provides surgeons with the desired tissue effects of cutting and coagulating tissue in laparoscopic procedures, while preventing stray electrosurgical energy that can cause complications and even death. It produces and markets a full line of AEM Instruments, which are shielded and monitored to prevent stray electrosurgical burns from insulation failure and capacitive coupling. Its product line includes a range of endo-mechanical instruments, such as scissors, graspers and dissectors, fixed-tip electrodes and suction-irrigation electrodes.
Directors
- Gregory Trudel PRE (60)
- David Newton CFD (74)
- Brian Jackman VPR (38)
- Mala Ray CTR (63)
- Robert Fries IND (72)
- Vern Kornelsen IND (88)
- Patrick Pace IND (49)
- Last Annual
- March 31st, 2024
- Last Interim
- June 30th, 2024
- Incorporated
- February 1st, 1991
- Public Since
- June 25th, 1996
- No. of Shareholders
- 68
- No. of Employees
- 22
- Sector
- Healthcare Equipment & Supplies
- Industry
- Healthcare
- Exchange
Pink Sheets on Nasdaq- Shares in Issue
- 11,875,143
- Address
- 6797 Winchester Circle, BOULDER, 80301
- Web
- https://www.encision.com/
- Phone
- +1 3034442600
- Auditors
- GreenGrowth CPAs
Upcoming Events for ECIA
Q3 2025 Encision Inc Earnings Release
Similar to ECIA
Aamaxan Transport
Pink Sheets on Nasdaq
ACCUSTEM SCIENCES
Pink Sheets on Nasdaq
Acutus Medical
Pink Sheets on Nasdaq
ADM Tronics Unlimited
Pink Sheets on Nasdaq
Advanced Biomedical Technologies
Pink Sheets on Nasdaq
FAQ
What is the Encision share price?
As of Today at 20:56 UTC, shares in Encision are trading at $0.37. This share price information is delayed by 15 minutes.
How has the Encision share price performed this year?
Shares in Encision last closed at $0.37 and the price had moved by -19.97% over the past 365 days. In terms of relative price strength the Encision share price has underperformed the S&P500 Index by -33.12% over the past year.
What are the analyst and broker recommendations for Encision?
There is no consensus recommendation for this security.
Find out moreWhat is the Encision dividend yield?
Encision does not currently pay a dividend.
Does Encision pay a dividend?
Encision does not currently pay a dividend.
When does Encision next pay dividends?
Encision does not currently pay a dividend.
How do I buy Encision shares?
To buy shares in Encision you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Encision?
As of the previous close price of $0.37, shares in Encision had a market capitalisation of $4.37m.
Where are Encision shares listed?
Here are the trading details for Encision:
- Country of listing: United States
- Exchange: PNK
- Ticker Symbol: ECIA
What kind of share is Encision?
Based on an overall assessment of its quality, value and momentum Encision is currently classified as a Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Encision share price forecast for 2024?
We could not find analyst target price data for this security.
Find out moreWhat is the trend in the Encision share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Encision. Over the past six months, its share price has underperformed the S&P500 Index by -24.29%.
As of the last closing price of $0.37, shares in Encision were trading -14.9% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Encision PE Ratio?
The Encision PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $0.37.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Encision?
Encision's management team is headed by:
- Gregory Trudel - PRE
- David Newton - CFD
- Brian Jackman - VPR
- Mala Ray - CTR
- Robert Fries - IND
- Vern Kornelsen - IND
- Patrick Pace - IND